Zacks Analyst Blog Highlights: Evergreen Solar, Onyx Pharmaceuticals, Pfizer and Double Eagle Petroleum.CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day, the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Evergreen Solar Evergreen Solar, Inc., founded in 1994,[1] develops, manufactures and markets solar power products enabled by its String Ribbon technology that provide environmentally clean electric power throughout the world. (Nasdaq:ESLR ESLR Expected Schoolwide Learning Results ESLR Equivalent Slr ), Onyx Pharmaceuticals (Nasdaq:ONXX), Pfizer (NYSE NYSE See: New York Stock Exchange :PFE 1. (text, editor) PFE - Programmer's File Editor. 2. (language) PFE - Portable Forth Environment. ) and Double Eagle Petroleum (Nasdaq:DBLE DBLE Double ). See the latest posts to the Analyst Blog by visiting: http://at.zacks.com/?id=2673. Here are highlights from Thursday's Analyst Blog: Evergreen Solar Rates a Buy The growth potential for the solar industry as a whole, and Evergreen Solar (Nasdaq: ESLR) in particular remains a compelling story. Burgeoning revenue and a much improved net earnings make it one of the fastest-growing alternative energy stocks going into 2007. Positives include significant new multi-year sales contracts, capacity expansions at EverQ over the next few years, improving operating efficiencies, technological upgrades, and a new silicon supply contract. However, continuing earnings losses and stock-based compensation expenses partially moderate its upside potential Upside potential The amount by which analysts or investors expect the price of a security may increase. upside potential The potential price or gain that may be expected in a security or in a security average, generally stated as the dollar over the near-term. Accordingly, we upgrade ESLR to Buy with a six-month target price of $9.75. Upgrade for ONXX We are optimistic about the potential of Onyx Pharmaceuticals' (Nasdaq:ONXX) oncology candidate Nexavar (sorafenib) due to its better than expected performance in the third quarter of 2006. However, we are cautious on the future for Nexavar. Unfortunately, the drug has entered a highly competitive market, and data on Pfizer's (NYSE:PFE) Sutent at ASCO ASCO American Society of Clinical Oncology ASCO Association of Schools and Colleges of Optometry (since 1941; Rockville, Maryland) ASCO Australian Standard Classification of Occupations ASCO Automatic Switch Company outshined that of Nexavar. We believe Nexavar sales will continue to grow over the next several years, but fail to achieve meaningful penetration unless additional clinical trials demonstrate utility in other indications. We upgrade the shares from Sell to Hold based on the third quarter performance of Nexavar. Our target price is $21. A Buy on Double Eagle Double Eagle Petroleum (Nasdaq:DBLE) released slightly better than expected third-quarter results this morning. Compared to the year-earlier quarter, production, realized pricing, and diluted EPS (Encapsulated PostScript) A PostScript file format used to transfer a graphic image between applications and platforms. EPS files contain PostScript code as well as an optional preview image in TIFF, WMF, PICT or EPSI, the latter being an ASCII-only format. are down. Compared with our estimates however, the numbers are a slightly positive surprise. Diluted EPS came in at $0.04, compared to our estimate of $0.03 and comparable earnings of $0.11. Both production and G&A expenses were lower than we expected. Average realized pricing was $5.49 per Mcfe, down YoY but higher than we expected. Though no significant project updates were given in the release, we hope to hear word on the progression of Cow Creek's EIS (1) (Executive Information System) An information system that consolidates and summarizes ongoing transactions within the organization. It provides top management with all the information it requires at all times from internal and external sources. during today's call. See the latest posts to the Analyst Blog by visiting http://at.zacks.com/?id=2645. About Zacks Equity Research Zacks Equity Research provides the best of quantitative and qualitative analysis Qualitative Analysis Securities analysis that uses subjective judgment based on nonquantifiable information, such as management expertise, industry cycles, strength of research and development, and labor relations. to help investors know what stocks to buy and which to sell for the long-term. Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons. Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=2674. About Zacks Zacks.com is a property of Zacks Investment Research Zacks Investment Research A firm that compiles earnings estimates and brokerage firm investment recommendations for thousands of publicly traded firms. , Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion